2月以来,复宏汉霖(2696.HK,股价20.05港元,市值109亿港元)在海外市场接连取得多项进展。先是帕妥珠单抗生物类似药HLX11的美国生物制品许可申请(BLA)获美国食品药品监督管理局(FDA)受理,紧接着抗PD-1单抗H药(汉斯状)在欧盟获得上市批准用于一线治疗广泛期小细胞肺癌(ES-SCLC),并与印度知名药企Dr.Reddy's就达雷妥尤单抗生物类似药HLX15签署覆盖美国及欧洲多国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.